Meeting
2018 ASCO Annual Meeting
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.
Authors
Kirsten Timms
Myriad Genetics, Salt Lake City, UT
Kirsten Timms , Jessica S Brown , Darren R. Hodgson , J Carl Barrett , Tsveta Milenkova , Jonathan A. Ledermann , Charlie Gourley , Eric Pujade-Lauraine , Michael Perry , Alexander Gutin , Victor Abkevich , Jerry S Lanchbury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
SOLO2 (NCT01874353), Study 19 (NCT00753545).
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5563)
DOI
10.1200/JCO.2018.36.15_suppl.5563
Abstract #
5563
Poster Bd #
290
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).
First Author: Brian Dougherty
Poster
2018 ASCO Annual Meeting
Analysis of tumor samples from SOLO2: Concordance of BRCA mutation (BRCAm) detection in tumor vs. blood and frequency of BRCA-specific loss of heterozygosity (LOH) and loss of function somatic mutations.
First Author: Darren R. Hodgson
Poster
2014 ASCO Annual Meeting
SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).
First Author: Kathleen N. Moore
Poster
2013 ASCO Annual Meeting
Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
First Author: Jung-min Lee